RAPT Therapeutics Inc (NAS:RAPT)
$ 4.18 -0.305 (-6.8%) Market Cap: 145.90 Mil Enterprise Value: 10.64 Mil PE Ratio: 0 PB Ratio: 1.12 GF Score: 42/100

Rapt Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 07:00PM GMT
Navin Jacob
UBS - Analyst

Good afternoon. Welcome to the UBS Global Healthcare Conference. The next session is with RAPT Therapeutics. My name is Navin Jacob. I cover SMID-cap biotech and large-cap pharma here at UBS. Thank you for joining us.

And from RAPT, I'm very pleased to have with us today, CEO and Founder, Brian Wong; and CFO, Rodney Young, as well. We're going to do a presentation -- just to provide folks who are not as familiar with RAPT, we're going to do about 25 minutes of presentation in slides, which you can see on the slide tab. And then after that, we'll spend about 20 minutes of questions from me to the management team of RAPT.

And if you do have questions, for members of the audience, you can submit those questions via the system, and they will pop up as anonymous and I will read them out. And we can take it from there. And so, without further ado, Brian, go ahead. Thanks again for joining us.

Brian Wong
Rapt Therapeutics Inc - CEO and Founder

Yes, sure. Thanks, Navin. First of all, I'd like to thank the UBS team for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot